ES2161354T3 - Compuestos mimeticos de la hoja beta y su uso como inhibidores de proteasas. - Google Patents

Compuestos mimeticos de la hoja beta y su uso como inhibidores de proteasas.

Info

Publication number
ES2161354T3
ES2161354T3 ES96910566T ES96910566T ES2161354T3 ES 2161354 T3 ES2161354 T3 ES 2161354T3 ES 96910566 T ES96910566 T ES 96910566T ES 96910566 T ES96910566 T ES 96910566T ES 2161354 T3 ES2161354 T3 ES 2161354T3
Authority
ES
Spain
Prior art keywords
beta
protease inhibitors
beta sheet
mimetic compounds
sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96910566T
Other languages
English (en)
Spanish (es)
Inventor
Michael Kahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecumetics Ltd
Original Assignee
Molecumetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecumetics Ltd filed Critical Molecumetics Ltd
Application granted granted Critical
Publication of ES2161354T3 publication Critical patent/ES2161354T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
  • Paper (AREA)
ES96910566T 1995-03-24 1996-03-25 Compuestos mimeticos de la hoja beta y su uso como inhibidores de proteasas. Expired - Lifetime ES2161354T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41051895A 1995-03-24 1995-03-24
US54900695A 1995-10-27 1995-10-27

Publications (1)

Publication Number Publication Date
ES2161354T3 true ES2161354T3 (es) 2001-12-01

Family

ID=27021026

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96910566T Expired - Lifetime ES2161354T3 (es) 1995-03-24 1996-03-25 Compuestos mimeticos de la hoja beta y su uso como inhibidores de proteasas.

Country Status (8)

Country Link
EP (2) EP0815123B1 (enExample)
JP (4) JPH10508035A (enExample)
AT (1) ATE206433T1 (enExample)
AU (2) AU713530B2 (enExample)
CA (2) CA2215695C (enExample)
DE (1) DE69615671T2 (enExample)
ES (1) ES2161354T3 (enExample)
WO (1) WO1996030035A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
AU7604196A (en) * 1995-10-30 1997-05-22 Merck & Co., Inc. Novel inhibitors of peptide binding to mhc class ii proteins
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
GB9702377D0 (en) * 1996-02-23 1997-03-26 Zeneca Ltd Peptide derivatives
NZ332347A (en) 1996-06-07 2000-05-26 Zeneca Ltd Peptide derivatives containing a hydrophobic group, L-amino acid residues and modified L-amino acid residues
NZ332740A (en) 1996-06-18 2000-05-26 Warner Lambert Co heterocyclically substituted carbamate or sulphonamide derivatives
ES2262184T3 (es) * 1996-08-05 2006-11-16 Myriad Genetics, Inc. Utilizacion de mimeticos de hojas beta como inhibidores de proteasa y de kinasa o como inhibidores de factores de transcripcion.
EP1661566A3 (en) * 1996-08-05 2008-04-16 Myriad Genetics, Inc. Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
GB9621836D0 (en) 1996-10-19 1996-12-11 Zeneca Ltd Peptide compounds
GB9624562D0 (en) * 1996-11-27 1997-01-15 Zeneca Ltd Peptide derivatives
GB9625865D0 (en) * 1996-12-12 1997-01-29 Zeneca Ltd Peptides
ATE230414T1 (de) * 1998-02-12 2003-01-15 Molecumetics Ltd Mimetika von beta-faltblatt und verfahren zur verwendung davon
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
HUP0201295A3 (en) 1999-01-27 2002-10-28 Ortho Mcneil Pharm Inc Peptidyl heterocyclic ketones useful as tryptase inhibitors
US7309688B2 (en) 2000-10-27 2007-12-18 Johnson & Johnson Consumer Companies Topical anti-cancer compositions and methods of use thereof
WO2001064678A2 (en) * 2000-02-29 2001-09-07 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7192615B2 (en) 2001-02-28 2007-03-20 J&J Consumer Companies, Inc. Compositions containing legume products
US20120296067A1 (en) 2010-02-03 2012-11-22 Prism BioLab Co., Ltd. Compound capable of binding to naturally occurring denatured protein, and method for screening for the compound
ES2819218T3 (es) 2014-10-06 2021-04-15 Cortexyme Inc Inhibidores de lisina gingipaína
WO2017083433A1 (en) 2015-11-09 2017-05-18 Cortexyme, Inc. Inhibitors of arginine gingipain
KR102780603B1 (ko) 2016-09-16 2025-03-12 라이트하우스 파마슈티컬스, 인코포레이티드 리신 진지파인의 케톤 억제제

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA896851B (en) * 1988-09-14 1990-06-27 Hoffmann La Roche Use of ace-inhibitors

Also Published As

Publication number Publication date
EP0815123A1 (en) 1998-01-07
EP0815123B1 (en) 2001-10-04
JP2004131511A (ja) 2004-04-30
CA2215695C (en) 2003-09-16
JPH10508035A (ja) 1998-08-04
WO1996030035A1 (en) 1996-10-03
AU5371496A (en) 1996-10-16
AU712581B2 (en) 1999-11-11
CA2215695A1 (en) 1996-10-03
JP2000319295A (ja) 2000-11-21
ATE206433T1 (de) 2001-10-15
CA2215720A1 (en) 1996-10-03
JP4152900B2 (ja) 2008-09-17
DE69615671D1 (de) 2001-11-08
JPH10508034A (ja) 1998-08-04
DE69615671T2 (de) 2002-08-08
EP0817642A1 (en) 1998-01-14
AU713530B2 (en) 1999-12-02
AU5372996A (en) 1996-10-16

Similar Documents

Publication Publication Date Title
ATE206433T1 (de) Beta-schleifenähnliche verbindungen und deren verwendung als protease-inhibitoren
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
FI972390A0 (fi) Sytokiini nimeltä Lerk-7
EP1712623A3 (en) Selection of proteins using RNA-protein fusions
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
EP1159441B8 (en) Delivery of nucleic acids and proteins to cells
ATE293159T1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
ATE469981T1 (de) Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten
DK0996409T3 (da) Præparat til at forsinke hårvækst og tilsvarende anvendelse
PT973806E (pt) Modificacao de proteinas com locais protegidos
ATE368682T1 (de) Als 2f1 bezeichnetes rezeptorprotein
ATE532533T1 (de) Von antikörpern abgeleitete vektoren für den transfer von substanzen in zellen
BR0009421A (pt) Inibidores de ligação lfa-1 aos icams e uso dos mesmos
ATE262537T1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
DK0877803T3 (da) OB-proteinreceptor og relaterede sammensætninger og fremgangsmåder
AU7571998A (en) Rapid evaluation of the ratio of biological molecules
IL157047A0 (en) Methods and devices for quantitation of glycated protein
CA2529001A1 (en) Binding peptides: methods for their generation and use
SE9602822D0 (sv) New receptor
ATE305612T1 (de) Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
EP1023906A4 (en) POTENTIATOR FOR ANTI-TUMOR ANTIBODY LYMPHOID
FI971580A7 (fi) Stabiloiva väliaine virtsassa olevalle aGST:lle käytettäväksi entsyymi -immunokokeessa
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
ATE210465T1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
ATE306942T1 (de) Zusammensetzung zur in-vitro befruchtung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 815123

Country of ref document: ES